59
Participants
Start Date
August 20, 2013
Primary Completion Date
June 1, 2016
Study Completion Date
August 28, 2020
nilotinib
Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).
Novartis Investigative Site, Budapest
Novartis Investigative Site, Torino
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Genova
Novartis Investigative Site, Monza
Johns Hopkins Oncology Center ORA, Baltimore
UNC Chapel Hill, Chapel Hill
Novartis Investigative Site, Madrid
Nemours Childrens Hospital, Orlando
Novartis Investigative Site, Bordeaux
St. Mary's Hospital, West Palm Beach
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Padua
Nationwide Childrens Hospital, Columbus
Novartis Investigative Site, Muang
Novartis Investigative Site, Kuala Lumpur
Novartis Investigative Site, Lille
Novartis Investigative Site, Paris
University of Texas Southwestern Medical Center Oncology, Dallas
Cook Children's Medical Center Oncology, Fort Worth
Novartis Investigative Site, Poitiers
Loma Linda University Cancer Center, Loma Linda
Lucile Salter Packard Children's Hospital at Stanford, Palo Alto
Seattle Childrens Hospital, Seattle
Novartis Investigative Site, Moscow
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Sakyo Ku
Novartis Investigative Site, Shinjuku-ku
Novartis Investigative Site, Saitama
Novartis Investigative Site, Shizuoka
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Sutton
Novartis Investigative Site, Bristol
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY